Literature DB >> 6367456

Approaching the controversies in antibacterial management of cancer patients.

P A Pizzo, J Commers, D Cotton, J Gress, J Hathorn, J Hiemenz, D Longo, D Marshall, K J Robichaud.   

Abstract

The principles for management of infectious complications in cancer patients are continuing to evolve. The critical element includes the prompt institution of broad-spectrum antibiotic(s) empirically when granulocytopenic patients become febrile and continuation and modification of the regimen in patients with persistent fever and granulocytopenia. The view is presented that antibiotics provide systemic prophylaxis as well as therapy in persistently granulocytopenic patients and that they should be continued until all signs of infection have cleared or the granulocyte count has recovered. Such aggressive therapy, supplemented by continued evaluation and monitoring of the patient, can significantly reduce infection-relation morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367456     DOI: 10.1016/0002-9343(84)90663-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

1.  A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients.

Authors:  A Böhme; G Just-Nübling; L Bergmann; P M Shah; W Stille; D Hoelzer
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

Review 2.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

3.  Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.

Authors:  D Faulds; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 4.  New developments in the treatment of gram-negative bacteremia.

Authors:  M A Jacobson; L S Young
Journal:  West J Med       Date:  1986-02

5.  A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  B de Pauw; K Williams; J de Neeff; T Bothof; T de Witte; R Holdrinet; C Haanen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

6.  [Results of several different controlled studies with ceftazidime in the treatment of infections in immunosuppressed patients].

Authors:  B E de Pauw
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 7.  Supportive therapy in management of leukemias.

Authors:  V P Choudhry; N Desai
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

8.  Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection.

Authors:  E J Bow; T J Louie
Journal:  CMAJ       Date:  1987-09-01       Impact factor: 8.262

Review 9.  Antibacterial therapy in patients with malignancies.

Authors:  K H Mayer; S M Opal
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

10.  Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole.

Authors:  F Menichetti; A Del Favero; R Guerciolini; M Tonato; F Aversa; F Roila; R F Frongillo; M F Martelli; S Davis; S Pauluzzi
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.